Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $318000.0.

  • Akebia Therapeutics' Depreciation & Amortization (CF) fell 1239.67% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1564.76%. This contributed to the annual value of $1.5 million for FY2024, which is 776.03% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Depreciation & Amortization (CF) stood at $318000.0, which was down 1239.67% from $316000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Depreciation & Amortization (CF) registered a high of $513000.0 during Q1 2021, and its lowest value of $314000.0 during Q1 2025.
  • For the 5-year period, Akebia Therapeutics' Depreciation & Amortization (CF) averaged around $398736.8, with its median value being $398000.0 (2023).
  • Per our database at Business Quant, Akebia Therapeutics' Depreciation & Amortization (CF) skyrocketed by 75.57% in 2024 and then plummeted by 2100.0% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Depreciation & Amortization (CF) stood at $442000.0 in 2021, then fell by 7.69% to $408000.0 in 2022, then fell by 3.43% to $394000.0 in 2023, then fell by 14.97% to $335000.0 in 2024, then fell by 5.07% to $318000.0 in 2025.
  • Its last three reported values are $318000.0 in Q3 2025, $316000.0 for Q2 2025, and $314000.0 during Q1 2025.